US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inhibitor Therapeutics Inc.

0.0770

-0.0065-7.78%

Volume:22.57K

Turnover:1.74K

Market Cap:13.29M

PE:- -

High:0.0785

Open:0.0785

Low:0.0770

Close:0.0835

52wk High:0.1238

52wk Low:0.0351

Shares:172.57M

Float Shares:36.38M

Volume Ratio:0.82

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

ROE:-952.30%

ROA:-72.57%

PB:-6.72

PE(LYR):- -

Loading ...

Overview Company News Filings

Danantara Indonesia Assures No Layoffs at PT INTI

Inhibitor Therapeutics sues investor over failed $3 million stock financing

Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission

Inhibitor Therapeutics Provides Clinical, Formulation and Ip Update on Itraconazole Program for Gorlin Syndrome

THOMSON REUTERS

Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INTI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INTI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTI\",,,,,undefined,":{"symbol":"INTI","market":"US","secType":"STK","nameCN":"Inhibitor Therapeutics Inc.","latestPrice":0.077,"timestamp":1780689600000,"preClose":0.0835,"halted":0,"volume":22570,"delay":15,"changeRate":-0.07784431137724557,"floatShares":36378595,"shares":172573545,"eps":0,"marketStatus":"Closed","change":-0.0065,"latestTime":"06-05 16:00:00 EDT Delay","open":0.0785,"high":0.0785,"low":0.077,"amount":1742.09,"amplitude":0.017964,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":5,"adr":0,"exchange":"OTCQB","adjPreClose":0.0835,"volumeRatio":0.81966},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INTI\",,,,,undefined,":{"symbol":"INTI","floatShares":36378595,"roa":"-72.57%","roe":"-952.30%","lyrEps":0,"volumeRatio":0.81966,"shares":172573545,"dividePrice":0,"high":0.0785,"amplitude":0.017964,"preClose":0.0835,"low":0.077,"week52Low":0.0351,"pbRate":"-6.72","week52High":0.12375,"institutionHeld":0,"latestPrice":0.077,"eps":0,"divideRate":0,"volume":22570,"delay":15,"open":0.0785,"prevYearClose":0.045,"prevWeekClose":0.085,"prevMonthClose":0.085,"prevQuarterClose":0.1087,"fiveDayClose":0.085,"twentyDayClose":0.09,"sixtyDayClose":0.088},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INTI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-06","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-13","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-03-29","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711684800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-13","symbol":"INTI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699851600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INTI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INTI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INTI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638559544","title":"Danantara Indonesia Assures No Layoffs at PT INTI","url":"https://stock-news.laohu8.com/highlight/detail?id=2638559544","media":"Tempo","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638559544?lang=en_us&edition=fundamental","pubTime":"2026-05-25 23:05","pubTimestamp":1779721507,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-The head of the State-Owned Enterprises Regulatory Body, who also serves as the Chief Operating Officer  of DanantaraIndonesia, Dony Oskaria, stated that they are evaluating the closure of PT Industri Telekomunikasi Indonesia  and ensuring that no employees will be laid off.\"An assessment  is being conducted. It's being checked. As I mentioned about streamlining,\" said Dony when met at the Senayan Parliament Complex, Jakarta, on Monday, May 25, 2026, as reported by ANTARA.During the event, Dony mentioned that Danantara is currently verifying PT INTI. On the other hand, he ensures that no employees would be laid off at INTI.","market":"sg","thumbnail":"https://statik.tempo.co/data/2026/02/06/id_1457454/1457454_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/02/06/id_1457454/1457454_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2105402/danantara-indonesia-assures-no-layoffs-at-pt-inti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2105402/danantara-indonesia-assures-no-layoffs-at-pt-inti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["LU1992135399.USD","LU2272731600.USD","LU1992135472.HKD","BK4139","LU2211815571.USD","BK4585","BK4198","BK4588","COO","COO.AU","GB00BDT5M118.USD","LU2272731782.SGD","INTI","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624491315","title":"Inhibitor Therapeutics sues investor over failed $3 million stock financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624491315","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624491315?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074095,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics filed litigation on March 30, 2026 against an institutional investor tied to a failed financing.Transaction contemplated sale of 12,000,000 common shares at $0.25 per share.Financing also included a warrant to buy up to 7,000,000 additional shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6LspBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","INTI","BK7096","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624550074","title":"Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2624550074","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624550074?lang=en_us&edition=fundamental","pubTime":"2026-04-01 09:58","pubTimestamp":1775008699,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics outlined progress in a comparative pharmacokinetic clinical study for its proprietary itraconazole formulation in Gorlin syndrome, positioning it as final clinical step before a planned US NDA filing via FDA 505 pathway.Top-line comparative PK and relative bioavailability results will be presented in the future, expected around mid-May 2026, ahead of full clinical study report.Program aims to support more consistent drug exposure versus conventional itraconazole, using an amorphous formulation designed to improve solubility and absorption.Company also plans to file a new global patent application covering formulation composition, targeting stronger IP protection without ongoing royalty obligations if granted.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4cdwxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","BK4112","BK4588","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139","INTI","BK7508","BK7096","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624965532","title":"Inhibitor Therapeutics Provides Clinical, Formulation and Ip Update on Itraconazole Program for Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2624965532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624965532?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:44","pubTimestamp":1774986265,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA7DLFCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855234","title":"Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855234?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:04","pubTimestamp":1774519475,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics published its annual report on Form 10-K.Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8NdxCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTI","MYX.AU","BK4139","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}